The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway

Publisher： Bentham Science Publishers

E-ISSN： 2212-3938|3|2|132-143

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.3, Iss.2, 2008-05, pp. : 132-143

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future

By  

Current Cancer Drug Targets, Vol. 11, Iss. 5, 2011-01 ,pp. : 624-653

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibition of the VEGF/VEGFR Pathway Improves Survival in Advanced Kidney Cancer: A Systematic Review and Meta-Analysis

By  

Current Drug Targets, Vol. 16, Iss. 2, 2015-01 ,pp. : 164-170

Bentham Science Publishers

Access to resources Recommend Favorite

Evolving Strategies in Manipulating VEGF/VEGFR Signaling for the Promotion of Angiogenesis in Ischemic Muscle

By  

Current Pharmaceutical Design, Vol. 15, Iss. 4, 2009-02 ,pp. : 411-421

Bentham Science Publishers

Access to resources Recommend Favorite

VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 15, Iss. 2, 2015-06 ,pp. : 135-144

Bentham Science Publishers

Access to resources Recommend Favorite

Molecular Design and Clinical Development of VEGFR Kinase Inhibitors

By  

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 14, 2007-07 ,pp. : 1379-1393

Bentham Science Publishers

Access to resources Recommend Favorite